TAIWANJ PHARMACEUTICALS CO., LTD. Financials TaiwanJ Pharmaceuticals Co., Ltd.
Equities
6549
TW0006549009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.8 TWD | -0.42% |
|
-5.22% | -20.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 463.4 | 804.8 | 1,003 | 758.9 | 796.3 | 1,108 |
| Enterprise Value (EV) 1 | 405.8 | 747.9 | 910.5 | 676.3 | 737.5 | 1,050 |
| P/E ratio | -1.89 x | -157 x | -22.3 x | -59.4 x | -8.61 x | -183 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 13,040,034 x | - | 34,407,590 x | 51,858,886 x | 48,722,606 x |
| EV / Revenue | - | 12,117,043 x | - | 30,664,935 x | 48,027,561 x | 46,187,297 x |
| EV / EBITDA | -3.67 x | 53.6 x | -23 x | -74.1 x | -36 x | -198 x |
| EV / FCF | -4.81 x | 157 x | -69 x | -184 x | 70.8 x | 487 x |
| FCF Yield | -20.8% | 0.64% | -1.45% | -0.54% | 1.41% | 0.21% |
| Price to Book | 3 x | 5.31 x | 5.7 x | 4.64 x | 11.1 x | 16.6 x |
| Nbr of stocks (in thousands) | 68,853 | 69,203 | 75,138 | 75,138 | 75,122 | 75,122 |
| Reference price 2 | 6.730 | 11.63 | 13.35 | 10.10 | 10.60 | 14.75 |
| Announcement Date | 19-04-17 | 20-04-16 | 21-04-07 | 22-04-12 | 23-05-25 | 24-03-20 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 61.72 | - | 22.06 | 15.36 | 22.74 |
| EBITDA 1 | -110.6 | 13.94 | -39.67 | -9.124 | -20.48 | -5.294 |
| EBIT 1 | -111.4 | -6.688 | -40.38 | -9.725 | -96.39 | -6.61 |
| Operating Margin | - | -10.84% | - | -44.09% | -627.77% | -29.07% |
| Earnings before Tax (EBT) 1 | -238.2 | 1.089 | -42.46 | -10.32 | -92.47 | -3.773 |
| Net income 1 | -238.2 | -5.083 | -42.46 | -12.42 | -92.47 | -6.047 |
| Net margin | - | -8.24% | - | -56.32% | -602.19% | -26.59% |
| EPS 2 | -3.564 | -0.0739 | -0.6000 | -0.1700 | -1.231 | -0.0805 |
| Free Cash Flow 1 | -84.39 | 4.75 | -13.2 | -3.675 | 10.41 | 2.155 |
| FCF margin | - | 7.7% | - | -16.66% | 67.79% | 9.47% |
| FCF Conversion (EBITDA) | - | 34.07% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-04-17 | 20-04-16 | 21-04-07 | 22-04-12 | 23-05-25 | 24-03-20 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 57.6 | 57 | 92.6 | 82.5 | 58.8 | 57.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -84.4 | 4.75 | -13.2 | -3.68 | 10.4 | 2.15 |
| ROE (net income / shareholders' equity) | -107% | -3.32% | -25.9% | -7.32% | -78.7% | -8.73% |
| ROA (Net income/ Total Assets) | -28.8% | -2.57% | -14.7% | -3.44% | -48.2% | -5.39% |
| Assets 1 | 828 | 197.7 | 288.6 | 361.2 | 191.9 | 112.2 |
| Book Value Per Share 2 | 2.240 | 2.190 | 2.340 | 2.180 | 0.9500 | 0.8900 |
| Cash Flow per Share 2 | 0.8400 | 0.8500 | 1.240 | 1.100 | 0.8100 | 0.7800 |
| Capex 1 | 0.32 | - | - | - | 1.23 | 1.44 |
| Capex / Sales | - | - | - | - | 7.98% | 6.34% |
| Announcement Date | 19-04-17 | 20-04-16 | 21-04-07 | 22-04-12 | 23-05-25 | 24-03-20 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 27.7M | |
| +7.68% | 113B | |
| +11.04% | 106B | |
| +0.41% | 22.27B | |
| -11.91% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.74% | 17.24B | |
| +6.75% | 14.29B | |
| +35.67% | 12.52B |
- Stock Market
- Equities
- 6549 Stock
- Financials TaiwanJ Pharmaceuticals Co., Ltd.